TITLE

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

AUTHOR(S)
Sominanda, A.; Hillert, J.; Fogdell-Hahn, A.
PUB. DATE
January 2008
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jan2008, Vol. 79 Issue 1, p57
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Development of neutralising antibodies (NAbs) against recombinant interferon-β (IFNβ) is a significant clinical problem in the treatment of multiple sclerosis (MS). Several methods are available to assess NAbs, but there is a lack of consensus on how the different NAb titre levels interfere with the efficacy of the drug, especially in the individual patient. Methods: NAb titres were measured with an in vitro MxA induction assay and the in vivo IFNβ response was assessed by measuring MxA mRNA expression using real-time PCR. Results: We identified titre levels of NAbs at which the IFNβ biological activity was reduced or abrogated. Patients with NAb titres of up to 150 TRU/ml (ten times reduction units per ml) still had retained IFNβ bioactivity, whereas greatly reduced levels of IFNβ bioactivity were found in patients with NAbs of 150-600 TRU/ml. Titres above 600 TRU/ml were associated with loss of IFNβ bioactivity. Similar results were obtained when TRAIL mRNA was used as a marker of the in vivo response to IFNβ. Conclusion: There is a stepwise loss of IFNβ bioactivity with increasing NAb titres and it is possible to identify functionally critical NAb titre levels that are useful to support treatment decisions at the individual patient level.
ACCESSION #
28741667

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics